Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X:
“Givastomig + Nivolumab + mFOLFOX in mGEC (Phase I/II).
- Bispecific CLDN18.2/4-1BB antibody
- ORR: 71% (up to 83% in expansion cohorts)
- Active in both low PD-L1 and low CLDN18.2
- Well-tolerated at all doses
- Deep, durable responses
- Ongoing 12 mg/kg.”
More posts featuring Galip Uyar.